Division of Lung Biology, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Division of Respiratory Medicine and Allergology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Respir Res. 2022 Mar 5;23(1):50. doi: 10.1186/s12931-022-01968-0.
A subset of individuals with allergic asthma develops a late phase response (LPR) to inhaled allergens, which is characterized by a prolonged airway obstruction, airway inflammation and airway hyperresponsiveness. The aim of this study was to identify changes in the plasma proteome and circulating hematopoietic progenitor cells associated with the LPR following inhaled allergen challenge.
Serial plasma samples from asthmatics undergoing inhaled allergen challenge were analyzed by mass spectrometry and immunosorbent assays. Peripheral blood mononuclear cells were analyzed by flow cytometry. Mass spectrometry data were analyzed using a linear regression to model the relationship between airway obstruction during the LPR and plasma proteome changes. Data from immunosorbent assays were analyzed using linear mixed models.
Out of 396 proteins quantified in plasma, 150 showed a statistically significant change 23 h post allergen challenge. Among the most upregulated proteins were three protease inhibitors: alpha-1-antitrypsin, alpha-1-antichymotrypsin and plasma serine protease inhibitor. Altered levels of 13 proteins were associated with the LPR, including increased factor XIII A and decreased von Willebrand factor. No relationship was found between the LPR and changes in the proportions of classical, intermediate, and non-classical monocytes.
Allergic reactions to inhaled allergens in asthmatic subjects were associated with changes in a large proportion of the measured plasma proteome, whereof protease inhibitors showed the largest changes, likely to influence the inflammatory response. Many of the proteins altered in relation to the LPR are associated with coagulation, highlighting potential mechanistic targets for future treatments of type-2 asthma.
一部分过敏性哮喘患者会对吸入性过敏原产生晚期反应(late phase response,LPR),其特征为气道阻塞延长、气道炎症和气道高反应性。本研究旨在确定与吸入性过敏原激发后 LPR 相关的血浆蛋白质组和循环造血祖细胞的变化。
对接受吸入性过敏原激发的哮喘患者的连续血浆样本进行质谱分析和免疫吸附测定。通过流式细胞术分析外周血单核细胞。使用线性回归分析质谱数据,以建立气道阻塞与血浆蛋白质组变化之间的关系模型。使用线性混合模型分析免疫吸附测定的数据。
在定量的 396 种血浆蛋白中,有 150 种在过敏原激发后 23 小时表现出统计学上的显著变化。上调最明显的蛋白包括三种蛋白酶抑制剂:α-1-抗胰蛋白酶、α-1-抗糜蛋白酶和血浆丝氨酸蛋白酶抑制剂。13 种蛋白的水平变化与 LPR 相关,包括因子 XIII A 的增加和 von Willebrand 因子的减少。LPR 与经典、中间和非经典单核细胞比例的变化之间没有关系。
哮喘患者吸入性过敏原反应与所测量的血浆蛋白质组的很大一部分变化有关,其中蛋白酶抑制剂的变化最大,可能影响炎症反应。许多与 LPR 相关的蛋白与凝血有关,突出了未来 2 型哮喘治疗的潜在机制靶点。